It’s way beyond that time of year again where I uncomfortably start to hit everyone up for our annual fund raising effort benefiting the Leukemia and Lymphoma Society in honor of Cutler. Without their research and support, the fight against blood cancers would not be anywhere as far along as it is. So, with the month of September being Blood Cancer awareness month it’s time for me to start pushing you for your help in eradicating blood cancers.
We invite you to join us as part of the team on November 1st in Frisco for a fun night of celebration and memory and helping raise awareness of the incredible work that LLS does on a daily basis. If you can’t join us, any donation of any size is greatly appreciated. Both efforts can be achieved by clicking on the link below.
I understand that donating to specific charities is a personal one and so to help motivate you, aside from Cutler’s story, please consider the below as some motivation and supporting factors for choosing LLS.
- LLS exists to find cures and ensure access to the best available treatments for the more than one million North Americans currently living with or are in remission from a blood cancer
- Last year alone, LLS invested nearly $74 million in cutting-edge research
- For more than 60 years, LLS has invested more than $1 billion to advance cancer therapies and save lives
- LLS is currently funding the work of Dr. Robert Collins at UT Southwestern in a revolutionary new study named Beat AML (What Cutler beat)
- Nearly 40% of new cancer therapies approved by the FDA between 2000 and 2013 were first approved for blood cancer patients
- LLS has helped advance laws in almost half of the states to ensure coverage and payment parity for cancer medications, regardless of how or where administered
- Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled or even quadrupled, thanks to the funding of LLS
- In 1964, the five-year survival rate for children with ALL was 3%. Today it’s approximately 90%
- In the last year alone, LLS invested $35.2 MILLION into leukemia research
- Hodgkin lymphoma survival rates have more than doubled, to 87%, since the 1960s
- LLS poured more than $20.4 MILLION into lymphoma research in the last year.
- The survival rate for myeloma more than tripled since the 1960s
- LLS funded myeloma researchers to the tune of nearly $10 MILLION last year alone
- LLS helped advance Gleevec® for patients with CML; this oral drug is now helping patients with other cancers
- LLS-funded researchers helped advance Rituxan ® (rituximab), an antibody that helps boost the immune system to attack cancer cells in patients with lymphoma and CLL
No ice water required to be poured over your head and no public pressure, just a simple request to make Someday Today and help join the fight.